On October 7, 2019 ImaginAb Inc., a clinical-stage immuno-oncology imaging company, reported publication of its data in leading peer-reviewed medical radiology publication, The Journal of Nuclear Medicine (JNM) (Press release, ImaginAb, OCT 7, 2019, View Source [SID1234540081]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The paper entitled "First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting[i]" reports the results from a first in-vivo clinical study to assess the safety, tolerability, and efficacy of ImaginAb’s lead product, CD8 tracer, 89Zr-Df-IAB22M2C, in visualizing the immune system.
The data from the Phase I trial reported in the paper demonstrated 89Zr-Df-IAB22M2C was well tolerated with no immediate or delayed side effects observed. In conclusion, the study found 89Zr- Df-IAB22M2C imaging to be safe and with favorable kinetics for early imaging. The biodistribution suggested successful targeting of CD8+ T cell-rich tissues. The observed targeting of tumor lesions suggests this may be informative for CD8+ T cell accumulation within tumors.
Lead author of the study, Neeta Pandit-Taskar, MD, Nuclear Medicine Physician at Memorial Sloan Kettering Cancer Center, said: "This novel imaging agent has the potential to non-invasively assess the presence of CD8 T cells in patients’ tumors and results of this initial assessment are encouraging. With more research, this technology may ultimately serve a critical role as a biomarker of immunotherapy outcome and inform clinical trials of novel immunotherapies that act mechanistically through the presence of CD8 T cells."
Ian Wilson, CEO of ImaginAb, added: "We are delighted that this paper has been published in The Journal of Nuclear Medicine, a highly regarded publication in the field of imaging and radiology. Our pioneering clinical trial involving patients at leading cancer therapy centers, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, and Honor Health, are furthering ImaginAb’s goal to provide target-specific imaging agents to predict, inform, monitor and enable treatment of cancer disease more effectively."
ImaginAb’s lead product, CD8 tracer 89Zr-Df-IAB22M2C, is a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells. Currently, in Phase II multi-center clinical trials at world-renowned imaging and cancer centers in North America, the 89Zr-Df-IAB22M2C immunoPET agent detects and visualizes CD8 T cells using ImaginAb’s ‘minibody’ technology. This provides highly-specific, quantitative assessment of the immunological status of individual cancer lesions within a patient, potentially enabling treatment to be tailored quickly and specifically to the needs of that patient.
Publication details: doi: 10.2967/jnumed.119.229781
For further information, please contact:
ImaginAb
Ian Wilson, CEO
Salli Walker, External Partnership Manager
Email: [email protected]
Phone: +1 310 645 1211
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Charlotte Hepburn-Scott
Email: [email protected]
Phone: +44 20 3950 9144